The impact of the coronavirus pandemic on Bayer AG's pharmaceuticals business has been worse than expected but as the German company presented a mixed set of financials for the second quarter, it also highlighted a couple of promising drugs, namely Nubeqa and finerenone, which offer promise for the future.
Pharmaceuticals sales for the second quarter came in at €3.99bn, down 9.7% and 7% lower than consensus analyst estimates. Like...








